- •Patients switching to natalizumab or fingolimod after ≥1 relapse were matched (1:1).
- •Outcomes were better for RMSS patients switching to natalizumab vs fingolimod.
- •Natalizumab patients had lower relapse rates and greater time to first relapse.
- •Relapse outcome differences were greatest in those with prior high-relapse activity.
Abbreviations:ARR (annualized relapse rate), BRACETD (Betaseron, Rebif, Avonex, Copaxone, Extavia, Tecfidera, Aubagio), CI (confidence interval), DMT (disease-modifying therapy), EDSS (Expanded Disability Status Scale), HR (hazard ratio), IPTW (inverse-probability-of-treatment-weighting), MRI (magnetic resonance imaging), OFSEP (Observatoire Français de la Sclérose en Plaques), RR (relative risk), RRMS (relapsing-remitting multiple sclerosis), RRR (relapse rate ratio), SD (standard deviation)
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
- The effectiveness of natalizumab vs fingolimod–a comparison of international registry studies.Mult. Scler. Relat. Disord. 2021; 53
- Comparative efficacy of fingolimod vs natalizumab: a French multicenter observational study.Neurology. 2016; 86: 771-778
- Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.Mult. Scler. 2016; 22: 1315-1326
- MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis.Mult. Scler. 2006; 12: 769-774
- The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a randomised, head-to-head phase 4 study.Mult. Scler. 2017; 23 ([abst P791]): 405-406
- Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.J. Neurol. Neurosurg. Psychiatry. 2014; 85: 1190-1197
- An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy.Mult. Scler. 2014; 20: 1381-1390
- The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study.Mult. Scler. Relat. Disord. 2019; 33: 146-152
- Brain health: time matters in multiple sclerosis.Mult. Scler. Relat. Disord. 2016; 9: S5-S48
- Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches.Neural Regen. Res. 2018; 13: 1871-1874
- Real-life clinical use of natalizumab and fingolimod in Austria.Acta Neurol. Scand. 2018; 137: 181-187
- The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: an observational study.PLoS One. 2017; 12e0176174
- Observational data: understanding the real MS world.Mult. Scler. 2016; 22: 1642-1648
- Switch to natalizumab versus fingolimod in active relapsing remitting multiple sclerosis.Ann. Neurol. 2015; 77: 425-435
- A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.N. Engl. J. Med. 2010; 362: 387-401
- A longitudinal real-life comparison study of natalizumab and fingolimod.Acta Neurol. Scand. 2017; 136: 217-222
- Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.BMC Med. Res. Methodol. 2022; 22: 155
- Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.Mult. Scler. 2018; 24: 777-785
- A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.N. Engl. J. Med. 2006; 354: 899-910
- The effects of natalizumab and fingolimod on clinical and MRI measures in relapsing remitting multiple sclerosis: a two-year comparative study.Eur. J. Neurol. 2017; 24 ([abst PR2091]): 579
- Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naive patients with multiple sclerosis.J. Neurol. 2017; 264: 284-294
- Natalizumab versus Fingolimod in patients with relapsing-remitting multiple sclerosis: a subgroup analysis from three international cohorts.CNS Drugs. 2021; 35: 1217-1232
- Efficacy of natalizumab and fingolimod in relapsing remitting multiple sclerosis in real world clinical setting.J. Neurol. Neurophysiol. 2015; 6: 1-6
- Treatment decisions in multiple sclerosis—insights from real-world observational studies.Nat. Rev. Neurol. 2017; 13: 105-118